Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial

Postmenopausal women on aromatase inhibitors (AI) are at risk of aromatase inhibitor-associated bone loss (AIBL) and fractures. In 2005 Osteoporosis Australia proposed an algorithm for bisphosphonate intervention. Three hundred and three postmenopausal women with early breast cancer (EBC) were enrol...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Bone Oncol
Main Authors: Lomax, Anna J., Yee Yap, Saw, White, Karen, Beith, Jane, Abdi, Ehtesham, Broad, Adam, Sewak, Sanjeev, Lee, Chooi, Sambrook, Philip, Pocock, Nicholas, Henry, Margaret J., Yeow, Elaine G., Bell, Richard
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2013
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4723379/
https://ncbi.nlm.nih.gov/pubmed/26909285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2013.08.001
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki